.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,840,680

« Back to Dashboard

Claims for Patent: 5,840,680

Title: ASP.sup.B28 insulin crystals
Abstract:The present invention relates to insulin crystals comprising ASP.sup.B28 and protamine, and pharmaceutical preparations containing same. The crystals and preparations exhibit rapid onset and prolonged activity when administered in vivo.
Inventor(s): Balschmidt; Per (Esper.ae butted.rde, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:08/763,853
Patent Claims: 1. Crystals comprising Asp.sup.B28 human insulin, protamine, and a member selected from the group consisting of phenol, a m-cresol, or a combination thereof.

2. Crystals as defined in claim 1, further comprising zinc.

3. A pharmaceutical formulation comprising crystals as defined in claim 1.

4. A pharmaceutical formulation comprising crystals as defined in claim 2.

5. A pharmaceutical formulation as defined in claim 3, wherein said crystals are suspended in an aqueous medium.

6. A pharmaceutical formulation as defined in claim 4, wherein said crystals are suspended in an aqueous medium.

7. A pharmaceutical formulation as defined in claim 3, further comprising a member selected from the group consisting of an isotonic agent, a buffer, and a combination thereof.

8. A pharmaceutical formulation as defined in claim 4, further comprising a member selected from the group consisting of an isotonic agent, a buffer, and a combination thereof.

9. A pharmaceutical formulation as defined in claim 7, wherein said isotonic agent is selected from the group consisting of sodium chloride and glycerol and said buffer comprises disodium monohydrogen phosphate.

10. A pharmaceutical formulation as defined in claim 8, wherein said isotonic agent is selected from the group consisting of sodium chloride and glycerol and said buffer comprises disodium monohydrogen phosphate.

11. A pharmaceutical formulation as defined in claim 3, further comprising dissolved Asp.sup.B28 human insulin.

12. A pharmaceutical formulation as defied in claim 4, further comprising dissolved Asp.sup.B28 human insulin.

13. A method of treating a patient suffering from diabetes mellitus, said method comprising administering to said patient a pharmaceutical composition as defined in claim 3.

14. A method of treating a patient suffering from diabetes mellitus, said method comprising administering to said patient a pharmaceutical composition as defined in claim 4.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc